| Journal | Annals of medicine and surgery (2012) |
| Study Type | Randomized Trial |
| Population | Human participants |
This is the first systematic review specifically examining CBD safety in healthy populations, filling a critical evidence gap. Most safety data comes from patient populations where underlying conditions may confound adverse event profiles.
This meta-analysis of four RCTs involving 269 healthy adults found CBD significantly increased diarrhea risk compared to placebo (RR = 5.85). The study focused on common adverse events including headache, fatigue, abdominal pain, and respiratory symptoms. While the sample size was modest and limited to healthy volunteers, this represents the most rigorous safety assessment of CBD in non-patient populations to date.
“This confirms what I observe clinically—diarrhea is CBD’s most predictable dose-limiting side effect, even in healthy individuals. The magnitude of risk increase aligns with my clinical experience across diverse patient populations.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
What studies and side effects did this CBD safety meta-analysis examine?
The meta-analysis combined four randomized controlled trials involving 269 healthy adults and compared CBD with placebo. It focused on common adverse events, including headache, fatigue, abdominal pain, and respiratory symptoms, as well as diarrhea.
Which side effect was most clearly linked to CBD in healthy adults?
Diarrhea was the clearest finding. Compared with placebo, CBD significantly increased the risk of diarrhea in healthy adults, with a relative risk (RR) of 5.85 across the four randomized trials included in the analysis.
Why study CBD safety in healthy people rather than patients?
Most CBD safety data come from patient populations, where underlying medical conditions may confound the pattern of adverse events. Studying healthy volunteers avoids that problem. The article describes this as the first systematic review specifically examining CBD safety in healthy populations, filling a critical evidence gap.
What are the main limitations of this CBD safety review?
The sample size was modest and the trials were limited to healthy volunteers, so the results may not describe how CBD affects people with medical conditions. Even with these limits, the article describes the analysis as the most rigorous safety assessment of CBD in non-patient populations to date.
Get the next evidence review in your inbox
Plain-language summaries of the newest cannabis research, written by a physician. Free to read, and you can unsubscribe at any time.
Join the growing cannabis community. Free. One-click subscribe. Delivered by Substack.
